Partnering with Artax
Our pipeline of first-in-class Nck modulator candidates is fully proprietary, with a convincing preclinical and clinical data package to date, and a first patient readout expected in 2024.
Novel mechanism of action effective across multiple diseases and strong composition of matter patent protection
Our pipeline of Nck modulators is breaking new ground across a wide array of T cell mediated autoimmune indications.
Interested in partnering with us? Get in touch!
We are interested in speaking with potential pharma partners about further development and commercialization of our first-in-class pipeline. Contact us at contact@artaxbiopharma.com
The latest news and publications from Artax
-
- Press Releases
Artax Biopharma completes patient recruitment in Phase 2a trial with first-in-class Nck modulator AX-158
AX-158 has broad potential to treat many autoimmune diseases without causing immunosuppression. Psoriasis biomarker panel and PASI scores… -
- Press Releases
Artax Biopharma Raises $8 Million Ahead of Phase 2a Data Expected in Q4-2024
Strong support from existing shareholders which includes Lilly, Advent Life Sciences, Columbus Ventures, Sound Bioventures and Belinda Termeer Cambridge,… -
- Blog
Oral Nck modulators: a new, unprecedented approach to autoimmune diseases
We all are searching for a universal way to treat autoimmune disease: an oral to…